RU2014141114A - Комбинированные виды терапии с использованием ингибиторов внеклеточного домена е-кадгерина - Google Patents

Комбинированные виды терапии с использованием ингибиторов внеклеточного домена е-кадгерина Download PDF

Info

Publication number
RU2014141114A
RU2014141114A RU2014141114A RU2014141114A RU2014141114A RU 2014141114 A RU2014141114 A RU 2014141114A RU 2014141114 A RU2014141114 A RU 2014141114A RU 2014141114 A RU2014141114 A RU 2014141114A RU 2014141114 A RU2014141114 A RU 2014141114A
Authority
RU
Russia
Prior art keywords
agent
pharmaceutical composition
cadherin
inhibits
secad
Prior art date
Application number
RU2014141114A
Other languages
English (en)
Russian (ru)
Inventor
Сабин БРУКСОН
Стефанос КИРКАНИДЕС
Original Assignee
Дзе Рисерч Фаундейшн Фор Дзе Стейт Юниверсити Оф Нью Йорк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Рисерч Фаундейшн Фор Дзе Стейт Юниверсити Оф Нью Йорк filed Critical Дзе Рисерч Фаундейшн Фор Дзе Стейт Юниверсити Оф Нью Йорк
Publication of RU2014141114A publication Critical patent/RU2014141114A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
RU2014141114A 2012-03-15 2013-03-15 Комбинированные виды терапии с использованием ингибиторов внеклеточного домена е-кадгерина RU2014141114A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261611390P 2012-03-15 2012-03-15
US61/611,390 2012-03-15
US201261736475P 2012-12-12 2012-12-12
US61/736,475 2012-12-12
PCT/US2013/032656 WO2013138790A1 (en) 2012-03-15 2013-03-15 Combination therapies including inhibitors of the extracellular domain of e-cadherin

Publications (1)

Publication Number Publication Date
RU2014141114A true RU2014141114A (ru) 2016-05-10

Family

ID=49161879

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014141114A RU2014141114A (ru) 2012-03-15 2013-03-15 Комбинированные виды терапии с использованием ингибиторов внеклеточного домена е-кадгерина

Country Status (8)

Country Link
US (2) US20150037354A1 (enExample)
EP (1) EP2844270A4 (enExample)
JP (1) JP2015514062A (enExample)
KR (1) KR20140138956A (enExample)
CN (1) CN104519899A (enExample)
CA (1) CA2867456A1 (enExample)
RU (1) RU2014141114A (enExample)
WO (1) WO2013138790A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9618514B2 (en) 2012-09-17 2017-04-11 Agios Pharmaceuticals, Inc Methods of evaluating patients using E-cadherin and vimentin
KR20150085078A (ko) 2012-11-21 2015-07-22 아지오스 파마슈티컬스 아이엔씨. 글루타마제 억제제 및 사용 방법
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
KR20160127149A (ko) 2014-03-21 2016-11-02 아지오스 파마슈티컬스 아이엔씨. 화합물 및 이의 사용 방법
WO2016008975A1 (en) * 2014-07-18 2016-01-21 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
CN111208283B (zh) * 2018-11-21 2023-09-26 中国科学院分子细胞科学卓越创新中心 增效的肿瘤抑制组合物及其应用
CN115040695B (zh) * 2021-03-09 2023-10-13 南开大学 一种基于VE-cad-Fc/N-cad-Fc的融合蛋白活性界面的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT414097B (de) * 2004-06-25 2006-09-15 Petzelbauer Peter Dr Pharmazeutische zubereitung zur behandlung von schock
US8455249B2 (en) * 2009-05-01 2013-06-04 The University Of Tokyo Highly effective anti-cadherin antibody for induction of antibody-dependent cellular cytotoxicity in vivo
KR20140075639A (ko) * 2010-10-27 2014-06-19 더 리서치 파운데이션 포 더 스테이트 유니버시티 오브 뉴욕 암 치료법을 위한 e-카드헤린의 가용성 세포외 도메인의 표적화 조성물 및 관련 방법

Also Published As

Publication number Publication date
US20150037354A1 (en) 2015-02-05
WO2013138790A1 (en) 2013-09-19
KR20140138956A (ko) 2014-12-04
CN104519899A (zh) 2015-04-15
JP2015514062A (ja) 2015-05-18
US20190008957A1 (en) 2019-01-10
EP2844270A4 (en) 2016-01-27
CA2867456A1 (en) 2013-09-19
EP2844270A1 (en) 2015-03-11

Similar Documents

Publication Publication Date Title
Rajaram et al. Epidermal growth factor receptor: Role in human cancer
Mackay et al. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND. 184
Cao et al. Ginsenoside Rg3 inhibits angiogenesis in a rat model of endometriosis through the VEGFR-2-mediated PI3K/Akt/mTOR signaling pathway
Joshi et al. Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells
AU2019226270B2 (en) Methods and compositions for prognosis, diagnosis and treatment of ADAM8-expressing cancer
Yan et al. Cancer-associated fibroblasts promote lymphatic metastasis in cholangiocarcinoma via the PDGF-BB/PDGFR-β mediated paracrine signaling network
Weng et al. RON and MET co-overexpression are significant pathological characteristics of poor survival and therapeutic targets of tyrosine kinase inhibitors in triple-negative breast cancer
RU2013123792A (ru) Композиции, нацеленные на растворимый внеклеточный домен е-кадгерина, и связанные с ними способы лечения онкологических заболеваний
Gourgue et al. Obesity and triple‐negative‐breast‐cancer: Is apelin a new key target?
JP2015514062A5 (enExample)
JP2023165937A (ja) Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤
US20260053761A1 (en) Use of thyromimetics for the treatment of cancer
ES2328159T3 (es) Inmunoglobulinas anti-epcam.
TR201802943T4 (tr) (S)-pirolidin-1,2-dikarboksilik asit 2-amid 1-({4-metil-5-[2-(2,2,2-trifloro-1,1-dimetil-etil)-piridin-4-il]-tiyazol-2-il}amid)'in egfr'ye bağlı hastalıkların veya egfr familya üyelerini hedefleyen ajanlara karşı direnç edinmiş hastalıkların tedavisinde kullanımı.
WO2014167030A1 (en) Anti-s100a7 antibodies for the treatment and diagnosis of cancer
CN110064045A (zh) 微肽cip2a-bp在治疗癌症中的应用
Yotsumoto et al. Efficacy of ligand-based targeting for the EGF system in cancer
Denduluri et al. Circulating biomarkers of bevacizumab activity in patients with breast cancer
WO2019233469A1 (zh) Pdgfr信号通路抑制剂用于制备治疗肠道炎症疾病的药物方面的用途
TWI842966B (zh) 一種具緩解抗癌藥物抗藥性及增加抗癌藥物敏感性之醫藥組合物及其用途
Ahmed et al. Potential effect of Imatinib on some sex hormones for male patients of Chronic Myelogenous Leukemia in Baghdad province
Wang et al. NRG1 secreted by cancer-associated fibroblasts contributes to enzalutamide resistance in prostate cancer cells
Schultz et al. Synergistic effects of imatinib and carboplatin on VEGF, PDGF and PDGF-Rα/ß expression in squamous cell carcinoma of the head and neck in vitro
US20150037336A1 (en) Combination of hb-egf binding protein and egfr inhibitor
US12540193B2 (en) Anti-ADAM8 antibodies and uses of the same

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20180112